Integrating Functional Assays in Early Oncology Discovery

The integration of functional assays into early-stage oncology drug discovery represents a paradigm shift from purely genomic and target-centric approaches toward more biologically holistic, phenotypically driven pipelines. Functional assays encompassing cell viability, apoptosis, proliferation, invasion, and patient-derived model systems provide critical mechanistic insights that complement genomic profiling and support the identification of clinically relevant therapeutic candidates.

Despite significant advances in oncology research, the attrition rate of drug candidates from early development to approval remains high. A key contributor to this challenge is the disconnect between preclinical efficacy and clinical outcomes, often arising from an over-reliance on biochemical binding assays that fail to capture the complexity of cancer biology in physiologically relevant contexts. Functional assays address this limitation by interrogating drug responses at the level of cellular and tissue behavior rather than isolated molecular interactions.

These assays span a continuum from classical two-dimensional (2D) cytotoxicity models to more advanced platforms such as three-dimensional multicellular tumor spheroids, microfluidic systems, and patient-derived organoids and ex vivo tumor samples. Their increasing integration into high-throughput and multiparametric workflows enables more comprehensive evaluation of compound activity and mechanism of action at earlier stages of discovery.

Historically, early oncology screening relied on simplified cell line panels, which enabled scalability but lacked the ability to recapitulate tumor heterogeneity, spatial architecture, and microenvironmental complexity. This limitation has driven the adoption of more physiologically relevant functional models that better mimic in vivo tumor conditions and improve translational predictivity.

This review examines the landscape of functional assay platforms employed in early oncology drug discovery, their integration within modern screening workflows, and the application of advanced three-dimensional and patient-derived systems. It also highlights key challenges, including assay standardization, tumor microenvironment recapitulation, and translational concordance, along with emerging strategies to address these limitations.

Figure 1: Integrated Early Oncology Drug Discovery Pipeline. Schematic overview of the integrated early oncology drug discovery pipeline, illustrating sequential and iterative stages from target identification to lead optimization. Functional assays are deployed prominently at Stages 2–5.

Oncology drug discovery is stratified into three principal target class architectures, distinguished by their biological rationale, assay dependencies, and approved drug precedents. Insight into these paradigms is essential for designing robust, fit-for-purpose functional screening cascades. Table 1 outlines the major target classes alongside representative agents and key assay considerations.

Table 1: Brief overview of primary target classes in Oncology Drug Discovery (Adapted from Mao et al., Signal Transduction and Targeted Therapy 2026 11:174)

Cell Viability and Cytotoxicity Assays

Cell viability assays represent the cornerstone of early oncology screening, providing quantitative readouts of compound-mediated cytotoxicity across cancer cell populations. These assays leverage distinct biological endpoints to infer cell death or growth inhibition:

• CellTiter-Glo (CTG Assay): This luminescence-based assay quantifies cellular ATP to indicate metabolic activity and cell viability. It offers superior sensitivity around 100x over colorimetric methods, compatibility with miniaturized 384 and 1536 well formats, and robustness in high-throughput screening cascades.
• Fluorescent exclusion assays: Dyes such as propidium iodide (PI) and SYTOX Green are excluded by intact plasma membranes enabling real-time fluorescent quantification of dead cells. Combined with live-cell imaging platforms (e.g., IncuCyte®, Operetta CLS), these assays enable kinetic viability profiling over multi-day periods, capturing drug-response dynamics and resistance emergence.

Apoptosis Profiling Assays

Mechanistic differentiation between apoptotic and necrotic cell death is critical for understanding a compound’s therapeutic mechanism and predicting tolerability in vivo. Apoptosis assays employed in early discovery include:

• Annexin V / Propidium Iodide (PI) Flow Cytometry: The most widely used apoptosis assay, leveraging the early apoptotic marker phosphatidylserine (PS) externalization (Annexin V binding) alongside membrane integrity loss (PI exclusion). Quadrant analysis distinguishes early apoptosis, late apoptosis/secondary necrosis, and primary necrosis populations, providing mechanistic clarity on drug action.
• Caspase-3/7 and Caspase-Glo® Assays: Executioner caspases (3 and 7) are activated during intrinsic and extrinsic apoptosis pathways. Luminescence-based caspase activity assays (Promega Caspase-Glo®) allow high-throughput quantification of apoptotic signalling in compound libraries. Multiplexed formats co-measuring caspase activation and viability enable the calculation of apoptosis index per viable cell.

Proliferation and Cell Cycle Assays

Differentiating between cytotoxic (cell-killing) and cytostatic (growth-arresting) mechanisms is essential for both efficacy characterization and dosing strategy design. Key assays include:

• EdU / BrdU Incorporation: Both 5-ethynyl-2ʹ-deoxyuridine (EdU) and bromodeoxyuridine (BrdU) are thymidine analogues incorporated into newly synthesized DNA during S-phase. Flow cytometric based detection of their incorporation provides quantitative S-phase fractions and enables cell cycle phase distribution analysis.
• Ki-67 Immunofluorescence: The nuclear protein Ki-67 is expressed in all phases of the active cell cycle (G1, S, G2, M) but absent in quiescent (G0) cells, making it a widely validated proliferation marker in both in vitro and translational tissue contexts.
• Clonogenic (Colony Formation) Assay: Considered the gold standard for quantifying reproductive cell survival after drug treatment, the clonogenic assay measures the ability of a single cell to proliferate into a colony of ≥50 cells. While low throughput, it provides unique information on long-term proliferative capacity and is particularly relevant for assessing radiation-sensitizing agents and DNA-damaging compounds.

Invasion, Migration, and Anchorage-Independent Growth Assays

Metastasis accounts for approximately 90% of cancer-related mortality, making the characterization of anti-invasive and anti-migratory drug activities a critical component of early discovery cascades. Functional invasion assays interrogate the hallmarks of metastatic behaviour:

• Invasion Assay: Cells are seeded in serum-free media on a Matrigel coated polycarbonate membrane; invasion toward a chemoattractant in the lower chamber is quantified after 24–48 hours. This format supports both single-endpoint and kinetic readouts and has been adapted to 96-well plate formats for higher throughput.
• Wound Healing / Scratch Assay: A defined scratch or wound is created in a confluent monolayer, and gap closure is monitored over time by live imaging.

Table 2:  Functional Assay Categories Employed in Early Oncology Discovery. Summary of major functional assay categories, representative platforms, and biological endpoints measured in early oncology drug discovery workflows.

Multiplex Signaling & Biomarker Assay Platforms

Beyond cellular phenotypic endpoints, early oncology discovery increasingly demands quantitative, mechanistic profiling of intracellular signaling networks, target engagement, and secreted biomarkers. Three highly complementary platform technologies such as Meso Scale Discovery (MSD) electrochemiluminescence, reporter gene assays, and AlphaLISA proximity-based immunoassays have become indispensable components of contemporary discovery cascades, enabling the translation of cellular phenotypes into mechanistic pharmacological understanding.

• Meso Scale Discovery (MSD): Electrochemiluminescence (ECL) technology represents a transformative advance in multiplexed quantitative protein detection for oncology drug discovery. MSD assays exploit the electrochemical excitation of SULFO-TAG™-labeled detection antibodies bound to analytes captured on carbon electrode-coated multi-array plates. Electrical stimulation of the electrode surface triggers photon emission exclusively from electrode-bound labels, enabling highly sensitive detection with minimal background achieving molar-level sensitivity for many analytes. The defining advantage of MSD over conventional ELISA is the capacity for true multiplex quantification: up to 10 analytes can be measured simultaneously from a single 25–50 μL sample well, enabling comprehensive pathway profiling from precious primary tumor material or limited PDO lysates. MSD U-PLEX and S-PLEX platforms extend this further, supporting up to 10-plex and ultra-sensitive single-analyte detection respectively, the latter achieving sensitivity improvements of 100–1000× over standard ELISA. In early oncology discover, MSD assays are most commonly deployed for phosphoprotein pathway profiling, cytokine and chemokine profiling in immuno-oncology and biomarker bridging from in vitro to clinical sample.
• Reporter Gene Assays: Reporter gene assays constitute a cornerstone of mechanism-of-action (MOA) characterization and transcription factor/pathway activity profiling in early oncology drug discovery. These cellular assays couple the activity of a signaling pathway of interest to the expression of a measurable reporter protein most commonly firefly luciferase, Renilla luciferase, secreted alkaline phosphatase (SEAP), or fluorescent proteins (GFP, mCherry) under the transcriptional control of a pathway-responsive promoter or response element. Reporter assays configurations are widely designed and can be chosen based on target and signaling pathway of interest.
• AlphaLISA (Amplified Luminescent Proximity Homogeneous Assay) technology, developed by PerkinElmer exploits the principle of singlet oxygen channelling between donor and acceptor beads held in proximity by a molecular interaction of interest. Upon laser excitation at 680 nm, photosensitizer compounds within the donor bead convert ambient oxygen to singlet oxygen species (¹O₂), which diffuse up to 200 nm through solution to reach acceptor beads, triggering a cascade of energy transfer reactions that culminate in light emission at 615 nm. This entirely homogeneous (no-wash) detection principle eliminates washing steps, reducing processing time, assay variability, and the risk of disrupting transient protein-protein interactions. In the early oncology discovery context, AlphaLISA assays offer several formats such as quantitative phosphoprotein detection in cell lysates, protein-protein interaction (PPI) profiling and for Proteolysis Targeting Chimera (PROTAC) target engagement and degradation.

All the above-mentioned multiplexing and biomarker assays are intrinsically compatible with miniaturized high-throughput formats i.e., 384-well assays require as little as 10 μL per well and adaptation to 1536-well format 2–5 μL per well and offer compound library screens of >100,000 compounds for compound mechanism confirmation and SAR driven compound identification.

Traditional two-dimensional monolayer cell culture, while experimentally amenable, fails to recapitulate key features of solid tumors including three-dimensional architecture, hypoxic gradients, cell-cell and cell-matrix interactions, and drug penetration barriers. The development of advanced three-dimensional and patient-derived model systems has profoundly expanded the functional resolution available to early drug discovery.

Three-Dimensional Spheroid Models

Multicellular tumor spheroids (MCTS) in ultra-low attachment (ULA) plates represent a significant advancement over monolayer models. Spheroids recapitulate oxygen and nutrient gradients characteristic of avascular tumor niches, generating a proliferating outer rim, a quiescent middle zone, and a necrotic core mirroring in-vivo tumor microarchitecture (Sutherland, 1988).

Drug penetration studies in spheroids have consistently demonstrated that compound efficacy profiles in 3D systems diverge substantially from 2D results, often identifying false positives (compounds active in 2D but inactive in 3D) at a rate that can exceed 60–70% for certain compound classes (Vinci et al., 2012; Edmondson et al., 2014). This makes spheroid counter-screening an essential early-stage gating step to enhance downstream predictive value.

High-content imaging platforms e.g., Operetta CLS™ equipped with confocal Z-stack capability enable automated quantification of spheroid volume, necrotic fraction, proliferating rim thickness, and caspase activation within intact spheroids providing multiparametric functional data from a single assay.

Patient-Derived Organoids (PDOs)

Patient-derived organoids represent the most biologically faithful ex vivo functional model system currently available for early oncology drug discovery. Derived from primary tumor tissue or tissue biopsies, organoids self-organize into three-dimensional structures that recapitulate the histological, genetic, and phenotypic diversity of the source tumor.

From an operational standpoint, PDOs are amenable to miniaturized drug screening in 96- and 384-well formats using automated liquid handling systems. Functional readouts include cell viability (ATP-based luminescence), apoptosis (Annexin V/ caspase), and morphological profiling by high-content imaging. The integration of PDO drug sensitivity data with matched genomic profiles enables simultaneous biomarker discovery alongside drug response characterization.

Table 3:  Comparative assessment of preclinical model systems across parameters critical to early oncology functional drug discovery. TME = Tumor Microenvironment.

Patient-Derived Xenografts (PDX) and In Vivo Functional Validation

Patient-derived xenograft (PDX) models established by direct engraftment of fresh human tumor tissue into immunodeficient mice represent the in vivo functional validation standard in early oncology discovery. PDX models preserve the genetic heterogeneity, histopathological architecture, and stromal interactions of the original tumor to a greater extent than any in vitro system.

The integration of functional assays into early oncology drug discovery is no longer optional, it is a scientific and strategic imperative. The mounting evidence that genomic information alone is insufficient to predict therapeutic efficacy has catalyzed the widespread adoption of biologically complex, phenotypically informative assay platforms throughout the discovery cascade.

From classical 2D cytotoxicity assays to patient-derived organoid drug sensitivity platforms the modern early oncology discovery toolkit offers unprecedented opportunities to interrogate drug biology in physiologically relevant contexts. The continued maturation of AI/ML tools for multiparametric data analysis, the development of TME-inclusive co-culture systems, and the scalability improvements in PDO and microfluidic platforms will progressively narrow the translational gap between bench and bedside.

Success will ultimately require the thoughtful integration of these platforms within rationally designed screening cascades, underpinned by rigorous standardization, cross-institutional data sharing, and close alignment between functional assay endpoints and clinical trial biomarker strategies. Done well, this integration holds genuine promise to meaningfully improve the historically poor clinical success rates in oncology drug development.

Aragen is a CRDMO specializing in integrated functional assay solutions that support early-stage oncology drug discovery and translational research. Our multi-modality expertise spans cell based functional profiling, including viability, apoptosis, proliferation, invasion, and multiplex biomarker assays, designed to generate mechanistically relevant data for confident decision making. By combining high-throughput screening with advanced analytical platforms, we help biopharma partners improve translational predictability, reduce development risk, and accelerate progression from discovery to clinical selection.

Partner with us to strengthen translational confidence from early discovery through clinical selection.